A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Eligibility Criteria

• * Participant ≥ 18 year
• * ECOG PS of 0 to 1
• * Provision of 'archival' tumor specimen
• * At least one measurable lesion according to RECIST v1.1,
• * Minimum life expectancy of 12 weeks
• * Adequate and stable cardiac function
• * Adequate bone marrow, liver and kidney function
• * Body weight ≥ 35 kg
• * Capable of giving signed informed consent
• * Any evidence of:
• * History or planned organ or allogeneic stem cell transplantation.
• * Active or prior documented autoimmune or inflammatory disorders, within the past 3 years
• * Any prior toxicities that led to permanent discontinuation of prior immunotherapy
• * Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy
• * Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids
• * Acute untreated or symptomatic malignant spinal cord compression, or a history of leptomeningeal carcinomatosis.
• * Active uncontrolled or chronic infection of hepatitis B, hepatitis C
• * Prior history of Grade ≥ 3 non-infectious pneumonitis.
• * Participant requires chronic immunosuppressive therapy (including steroids \> 10 mg prednisone/day or equivalent).
• * Receipt of live attenuated vaccine within 30 days.